@article {Badranpractneurol-2017-001713, author = {Abdul Badran and Carla Moran and Alasdair J Coles}, title = {Hypothyroid ataxia complicating monoclonal antibody therapy}, elocation-id = {practneurol-2017-001713}, year = {2017}, doi = {10.1136/practneurol-2017-001713}, publisher = {BMJ Publishing Group Ltd}, abstract = {We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the {\textquoteleft}immune checkpoint inhibitor{\textquoteright} class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.}, issn = {1474-7758}, URL = {https://pn.bmj.com/content/early/2017/10/21/practneurol-2017-001713}, eprint = {https://pn.bmj.com/content/early/2017/10/21/practneurol-2017-001713.full.pdf}, journal = {Practical Neurology} }